Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase I research study designed to determine the maximum tolerated dose (MTD) of
cisplatin, temsirolimus, and erlotinib in combination for treatment in triple negative breast
cancer (TNBC) patients.
Phase:
Phase 1
Details
Lead Sponsor:
Columbia University
Collaborators:
Genentech, Inc. Wyeth is now a wholly owned subsidiary of Pfizer